Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2A | P29274 | 6/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.34 |
| ▸ | ADORA1 | P30542 | 3/20 | 0.34 |
| ▸ | ACKR3 | P25106 | 1/20 | 0.34 |
| ▸ | ADORA2B | P29275 | 3/20 | 0.33 |
| ▸ | CHRM1 | P11229 | 3/20 | 0.33 |
| ▸ | PTGES | O14684 | 1/20 | 0.33 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.33 |
| ▸ | CNR1 | P21554 | 2/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23672722 | 0.89 | CNR1 (0.43) | CHRM1CNR1NTRK1 | |
| SCHEMBL23672982 | 0.88 | CNR1 (0.42) | CHRM1CNR1NTRK1 | |
| SCHEMBL23672693 | 0.87 | CHRM1 (0.42) | CHRM1CNR1NTRK1 | |
| SCHEMBL23672954 | 0.86 | ADORA2A (0.39) | ADORA2AMAPK1ADORA1ADORA2BCHRM1 | |
| SCHEMBL23672808 | 0.86 | ADORA2A (0.43) | ADORA2AADORA1ADORA2BADORA3CNR1 | |
| SCHEMBL23672885 | 0.85 | CHRM1 (0.39) | ADORA2AADORA2BCHRM1CNR1NTRK1 | |
| SCHEMBL23672919 | 0.85 | CHRM1 (0.44) | ADORA2AMAPK1ADORA2BCHRM1PTGES | |
| SCHEMBL23672673 | 0.82 | CHRM1 (0.42) | ADORA2AADORA1ADORA2BCHRM1 | |
| SCHEMBL23672593 | 0.82 | CHRM1 (0.43) | CHRM1 | |
| SCHEMBL23672946 | 0.82 | CHRM1 (0.49) | CHRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11111251-B2 | Positive allosteric modulators of the muscarinic acetylcholine receptor M1 | VANDERBILT UNIVERSITY (US) | 2021-09-07 | — | — | US | claimed |
| US-20210230180-A1 | POSITIVE ALLOSTERIC MODULATORS OF THE MUSCARINIC ACETYLCHOLINE RECEPTOR M1 | VANDERBILT UNIVERSITY | 2021-07-29 | — | — | US | claimed |
| EP-3416639-B1 | POSITIVE ALLOSTERIC MODULATORS OF THE MUSCARINIC ACETYLCHOLINE RECEPTOR M1 | UNIV VANDERBILT (US) | 2022-06-08 | — | — | EP | disclosed |
| US-11111251-B2 | Positive allosteric modulators of the muscarinic acetylcholine receptor M1 | VANDERBILT UNIVERSITY (US) | 2021-09-07 | — | — | US | disclosed |
| US-20210230180-A1 | POSITIVE ALLOSTERIC MODULATORS OF THE MUSCARINIC ACETYLCHOLINE RECEPTOR M1 | VANDERBILT UNIVERSITY | 2021-07-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210230180-A1 | POSITIVE ALLOSTERIC MODULATORS OF THE MUSCARINIC ACETYLCHOLINE RECEPTOR M1 | CHRM1, CHRM2, CHRM4 | ADORA2A 62/4885MAPK1 1889/4885ADORA1 56/4885 |
| US-11111251-B2 | Positive allosteric modulators of the muscarinic acetylcholine receptor M1 | CHRM1, CHRM2, CHRM4 | ADORA2A 62/4885MAPK1 1889/4885ADORA1 56/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.